Search

Your search keyword '"Stamos, Thomas D."' showing total 44 results
Start Over Author "Stamos, Thomas D."
44 results on '"Stamos, Thomas D."'

2. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial

Author

Lewis, Eldrin F., Claggett, Brian, Shah, Amil M., Liu, Jiankang, Shah, Sanjiv J., Anand, Inder, O’Meara, Eileen, Sweitzer, Nancy K., Rouleau, Jean L., Fang, James C., Desai, Akshay S., Retta, Tamrat M., Solomon, Scott D., Heitner, John F., Stamos, Thomas D., Boineau, Robin, Pitt, Bertram, and Pfeffer, Marc A.

Published
2018
Full Text
View/download PDF

15. Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients

Author

Duarte, Julio D., primary, Kansal, Mayank, additional, Desai, Ankit A., additional, Riden, Katherine, additional, Arwood, Meghan J., additional, Yacob, Alex A., additional, Stamos, Thomas D., additional, Cavallari, Larisa H., additional, Zamanian, Roham T., additional, Shah, Sanjiv J., additional, and Machado, Roberto F., additional

Published
2018
Full Text
View/download PDF

16. Cancer antigen-125 and risk of atrial fibrillation: a systematic review and meta-analysis

Author

Cheung, Angel, primary, Gong, Mengqi, additional, Bellanti, Roberto, additional, Ali-Hasan-Al-Saegh, Sadeq, additional, Li, Guangping, additional, Roig, Eulàlia, additional, Núñez, Julio, additional, Stamos, Thomas D, additional, Yilmaz, Mehmet Birhan, additional, Hakki, Kaya, additional, Wu, William K K, additional, Wong, Sunny Hei, additional, Wong, Wing Tak, additional, Bazoukis, George, additional, Lampropoulos, Konstantinos, additional, Tse, Lah Ah, additional, Zhao, Jichao, additional, Lip, Gregory Y H, additional, Baranchuk, Adrian, additional, Wong, Martin C S, additional, Liu, Tong, additional, and Tse, Gary, additional

Published
2018
Full Text
View/download PDF

19. Left ventricular global longitudinal strain predicts mortality and heart failure admissions in African American patients

Author

Kansal, Mayank M., primary, Mansour, Ibrahim N., additional, Ismail, Sahar, additional, Bress, Adam, additional, Wu, Grace, additional, Mirza, Omer, additional, Marpadga, Rahul, additional, Gheith, Hana, additional, Kim, Yoonsang, additional, Li, Yien, additional, Cavallari, Larisa, additional, and Stamos, Thomas D., additional

Published
2017
Full Text
View/download PDF

26. Association of Aldosterone Synthase Polymorphism (CYP11B2 -344T>C) and Genetic Ancestry with Atrial Fibrillation and Serum Aldosterone in African Americans with Heart Failure

Author

Bress, Adam, primary, Han, Jin, additional, Patel, Shitalben R., additional, Desai, Ankit A., additional, Mansour, Ibrahim, additional, Groo, Vicki, additional, Progar, Kristin, additional, Shah, Ebony, additional, Stamos, Thomas D., additional, Wing, Coady, additional, Garcia, Joe G. N., additional, Kittles, Rick, additional, and Cavallari, Larisa H., additional

Published
2013
Full Text
View/download PDF

39. Association of Aldosterone Synthase Polymorphism (CYP11B2 -344T>C) and Genetic Ancestry with Atrial Fibrillation and Serum Aldosterone in African Americans with Heart Failure.

Author

Bress, Adam, Han, Jin, Patel, Shitalben R., Desai, Ankit A., Mansour, Ibrahim, Groo, Vicki, Progar, Kristin, Shah, Ebony, Stamos, Thomas D., Wing, Coady, Garcia, Joe G. N., Kittles, Rick, and Cavallari, Larisa H.

Subjects
ALDOSTERONE synthesis, GENETIC polymorphisms, ATRIAL fibrillation, GENEALOGY, DISEASES in African Americans, HEART failure
Abstract

The objective of this study was to examine the extent to which aldosterone synthase genotype (CYP11B2) and genetic ancestry correlate with atrial fibrillation (AF) and serum aldosterone in African Americans with heart failure. Clinical data, echocardiographic measurements, and a genetic sample for determination of CYP11B2 -344T>C (rs1799998) genotype and genetic ancestry were collected from 194 self-reported African Americans with chronic, ambulatory heart failure. Genetic ancestry was determined using 105 autosomal ancestry informative markers. In a sub-set of patients (n = 126), serum was also collected for determination of circulating aldosterone. The CYP11B2 −344C allele frequency was 18% among the study population, and 19% of patients had AF. Multiple logistic regression revealed that the CYP11B2 −344CC genotype was a significant independent predictor of AF (OR 12.7, 95% CI 1.60–98.4, p = 0.0150, empirical p = 0.011) while holding multiple clinical factors, left atrial size, and percent European ancestry constant. Serum aldosterone was significantly higher among patients with AF (p = 0.036), whereas increased West African ancestry was inversely correlated with serum aldosterone (r = −0.19, p = 0.037). The CYP11B2 −344CC genotype was also overrepresented among patients with extreme aldosterone elevation (≥90th percentile, p = 0.0145). In this cohort of African Americans with chronic ambulatory heart failure, the CYP11B2 −344T>C genotype was a significant independent predictor of AF while holding clinical, echocardiographic predictors, and genetic ancestry constant. In addition, increased West African ancestry was associated with decreased serum aldosterone levels, potentially providing an explanation for the lower risk for AF observed among African Americans. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

42. Abstract 315

Author

Mansour, Ibrahim N, Gheith, Hana H, Dowdy, Zachary, Dickens, Carolyn, and Stamos, Thomas D

Abstract

Background:Anemia is a frequently encountered comorbidity that affects both death and hospitalization in patients with heart failure (HF). The effect of anemia on 30-day hospital readmission in African Americans (AA) with HF has not been studied.

Published
2014

43. Cancer antigen-125 and risk of atrial fibrillation: a systematic review and meta-analysis

Author

William K.K. Wu, Eulalia Roig, Guangping Li, Gregory Y.H. Lip, Julio Núñez, Tong Liu, Kaya Hakki, Jichao Zhao, Mengqi Gong, Thomas D. Stamos, Martin C.S. Wong, Konstantinos Lampropoulos, Sadeq Ali-Hasan-Al-Saegh, Gary Tse, Sunny H. Wong, George Bazoukis, Angel Cheung, Mehmet Yilmaz, Wing Tak Wong, Roberto Bellanti, Adrian Baranchuk, Lah Ah Tse, [Cheung, Angel] Brown Univ, Dept Biomed Engn, Providence, RI 02912 USA -- [Gong, Mengqi -- Li, Guangping -- Liu, Tong] Tianjin Med Univ, Dept Cardiol, Tianjin Key Lab Ion Mol Funct Cardiovasc Dis, Tianjin Inst Cardiol,Hosp 2, Tianjin, Peoples R China -- [Bellanti, Roberto] Cambridge Univ Hosp NHS Trust, Dept Med, Cambridge, England -- [Ali-Hasan-Al-Saegh, Sadeq] Shahid Sadoughi Univ Med Sci, Cardiovasc Res Ctr, Yazd, Iran -- [Roig, Eulalia] Hosp Santa Creu & Sant Pau, Inst Recerca Biomed St Pau, Cardiol Dept, Barcelona, Spain -- [Roig, Eulalia] Univ Autonoma Barcelona, Barcelona, Spain -- [Nunez, Julio] Univ Valencia, Cardiol Dept, Dept Med, Hosp Clin Univ, Valencia, Spain -- [Nunez, Julio] CIBER Cardiovasc Dis CIBERCV, Madrid, Spain -- [Stamos, Thomas D.] Univ Illinois, Dept Cardiol, Chicago, IL USA -- [Yilmaz, Mehmet Birhan -- Hakki, Kaya] Cumhuriyet Univ, Dept Cardiol, Med Sch, Sivas, Turkey -- [Wu, William K. K.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Fac Med, Hong Kong, Peoples R China -- [Wu, William K. K. -- Wong, Sunny Hei -- Tse, Gary] Chinese Univ Hong Kong, Fac Med, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China -- [Wong, Sunny Hei -- Tse, Gary] Chinese Univ Hong Kong, Fac Med, Dept Med & Therapeut, Hong Kong, Peoples R China -- [Wong, Wing Tak] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Peoples R China -- [Bazoukis, George -- Lampropoulos, Konstantinos] Evangelismos Gen Hosp Athens, Dept Cardiol 2, Lab Cardiac Electrophysiol, Athens, Greece -- [Tse, Lah Ah] Chinese Univ Hong Kong, Div Occupat & Environm Hlth, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China -- [Zhao, Jichao] Univ Auckland, Auckland Bioengn Inst, Auckland, New Zealand -- [Lip, Gregory Y. H.] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England -- [Lip, Gregory Y. H.] Aalborg Univ, Aalborg Thrombosis Res Unit, Dept Clin Med, Aalborg, Denmark -- [Baranchuk, Adrian] Queens Univ, Div Cardiol, Kingston Gen Hosp, Kingston, ON, Canada -- [Wong, Martin C. S.] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China, Wong, Martin -- 0000-0001-7706-9370, and Tse, Gary -- 0000-0001-5510-1253

Subjects
medicine.medical_specialty, business.industry, Cancer, Atrial fibrillation, 030204 cardiovascular system & hematology, medicine.disease, Mean difference, Cancer antigen, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Meta-analysis, Internal medicine, Journal Article, Medicine, Sinus rhythm, In patient, Cardiology and Cardiovascular Medicine, Prospective cohort study, business, Original Research
Abstract

WOS: 000458034100002, Background Cancer antigen-125 (Ca-125) is traditionally recognised as a tumour marker and its role in cardiovascular diseases has been studied only in recent years. Whether Ca-125 is elevated in patients with atrial fibrillation (AF) and its levels predict the risk of AF remains controversial. Therefore, we conducted a systematic review and meta-analysis of the association between Ca-125 levels and AF. Methods PubMed and EMBASE databases were searched until 1 June 2017 for studies that evaluated the association between Ca-125 and AF. Inclusion criteria included studies that compare Ca-125 in patients with and without AF, or those reporting HRs/ORs for risk of AF stratified by Ca-125 levels. Results A total of 39 entries were retrieved from the databases, of which 10 studies were included in the final meta-analysis. Ca-125 was significantly higher in patients with AF compared with those in sinus rhythm (mean difference=16 U/mL, 95% CI 2 to 30 U/mL, P, Croucher Foundation of Hong Kong [81570298]; National Natural Science Foundation of China, GT and SHW are supported by the Croucher Foundation of Hong Kong. This work was supported by a research grant (Number: 81570298) from the National Natural Science Foundation of China to TL.

Published
2018

44. Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.

Author

Cavallari LH, Momary KM, Groo VL, Viana MA, Camp JR, and Stamos TD

Subjects
Adrenergic beta-Antagonists administration & dosage, Adult, Aged, Atenolol administration & dosage, Atenolol pharmacology, Carbazoles administration & dosage, Carbazoles pharmacology, Carvedilol, Diuretics administration & dosage, Dose-Response Relationship, Drug, Female, Fibrosis physiopathology, Humans, Male, Metoprolol administration & dosage, Metoprolol pharmacology, Middle Aged, Peptide Fragments blood, Peptide Fragments drug effects, Procollagen blood, Procollagen drug effects, Propanolamines administration & dosage, Propanolamines pharmacology, Prospective Studies, Radioimmunoassay, Spironolactone administration & dosage, Adrenergic beta-Antagonists pharmacology, Diuretics pharmacology, Heart Failure drug therapy, Peptide Fragments metabolism, Procollagen metabolism, Spironolactone pharmacology
Abstract

Study Objective: To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure., Design: Prospective clinical study., Setting: Two heart failure centers., Patients: Eighty-eight spironolactone-naïve patients with heart failure who were taking beta-blockers., Intervention: In a subset of 29 patients, spironolactone was started at 12.5 mg/day, with the dosage titrated to 25 mg/day if tolerated., Measurements and Main Results: Venous blood samples were collected from each patient. Serum procollagen type I and type III aminoterminal peptides (PINP and PIIINP) were determined by radioimmunoassay and compared between the 25 patients receiving low doses (< 50% of recommended target dose) and the 63 patients receiving high doses (> or = 50% of recommended target dose) of beta-blockers. Patients receiving low-dose beta-blockers had higher mean +/- SD PIIINP concentrations (6.6 +/- 3.5 vs 4.9 +/- 2.6 microg/L, p=0.03) and tended to have higher PINP concentrations (74.0 +/- 44.1 vs 57.1 +/- 28.6 microg/L, p=0.10) compared with those receiving high doses. A repeat blood sample was collected from the 29 patients who received spironolactone after 6 months of therapy. Changes in procollagen peptides also were compared in this subset between low-dose (9 patients) and high-dose (20 patients) beta-blocker groups. Low beta-blocker doses were associated with greater reductions in concentrations of PINP (median [intraquartile range] -14.3 microg/L [-9.8 to -19.3 microg/L] vs -2.5 microg/L [5.9 to -9.8 microg/L], p=0.02) and PIIINP (-1.4 microg/L [-0.9 to -2.4 microg/L] vs 0.1 microg/L [0.9 to -1.3 microg/L], p=0.045) with spironolactone therapy than high beta-blocker doses. In addition, 100% of the patients in this subset taking low-dose beta-blockers versus only 35% taking higher doses had reductions in both markers of cardiac fibrosis., Conclusion: Spironolactone may benefit patients with heart failure who cannot tolerate upward titration of beta-blocker dosages, at least in terms of its effects on cardiac remodeling.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results